Conditioned medium of human menstrual blood-derived endometrial stem cells protects against cell inflammation and apoptosis of Npc1KO N2a cells
AbstractNiemann-Pick disease type C1 (NPC1) is a hereditary neurodegenerative disorder caused by a mutation in theNPC1 gene. This gene encodes a transmembrane protein found in lysosomes. This disease characterized by hepatosplenomegaly, neurological impairments and premature death. Recent preclinical studies have shown promising results in using mesenchymal stem cells (MSCs) to alleviate the symptoms of NPC1. One type of MSCs, known as human menstrual blood-derived endometrial stem cells (MenSCs), has attracted attention due to its accessibility, abundant supply, and strong proliferation and regeneration capabilities. Howe...
Source: Metabolic Brain Disease - June 1, 2023 Category: Neurology Source Type: research
Correction to: Indian ginseng (Withania somnifera) supplementation ameliorates oxidative stress and mitochondrial dysfunctions in experimental model of stroke
(Source: Metabolic Brain Disease)
Source: Metabolic Brain Disease - June 1, 2023 Category: Neurology Source Type: research
Conditioned medium of human menstrual blood-derived endometrial stem cells protects against cell inflammation and apoptosis of Npc1KO N2a cells
AbstractNiemann-Pick disease type C1 (NPC1) is a hereditary neurodegenerative disorder caused by a mutation in theNPC1 gene. This gene encodes a transmembrane protein found in lysosomes. This disease characterized by hepatosplenomegaly, neurological impairments and premature death. Recent preclinical studies have shown promising results in using mesenchymal stem cells (MSCs) to alleviate the symptoms of NPC1. One type of MSCs, known as human menstrual blood-derived endometrial stem cells (MenSCs), has attracted attention due to its accessibility, abundant supply, and strong proliferation and regeneration capabilities. Howe...
Source: Metabolic Brain Disease - June 1, 2023 Category: Neurology Source Type: research
Correction to: Indian ginseng (Withania somnifera) supplementation ameliorates oxidative stress and mitochondrial dysfunctions in experimental model of stroke
(Source: Metabolic Brain Disease)
Source: Metabolic Brain Disease - June 1, 2023 Category: Neurology Source Type: research
Closing spontaneous portosystemic shunts in cirrhosis: Does it make sense? Does it work? What does it take?
AbstractSpontaneous portosystemic shunts (SPSS) are an often neglected cause of hepatic encephalopathy associated with cirrhosis. Nowadays, SPSS are considered as radiological biomarkers of clinically significant portal hypertension rather than the previous dogmatic perceived decompressive vessels. SPSS are not rare as they can be diagnosed in over 60% of the patients with cirrhosis by mere contrast-enhanced CT. Moreover, they are clinically relevant since they impact on all portal hypertensive related complications, in particular medically refractory HE, and represent an independent predictor of decompensation and mortali...
Source: Metabolic Brain Disease - May 17, 2023 Category: Neurology Source Type: research
Albumin therapy for hepatic encephalopathy: current evidence and controversies
AbstractHepatic encephalopathy (HE) is a common complication that occurs in 16 –21% of end-stage cirrhosis patients. Emerging evidence suggests that systemic inflammation and oxidative stress may play a role in the development of HE. Recent understanding on the anti-inflammatory properties of human albumin has led to growing interest of using human albumin for the treatment and prevention of HE among decompensated patients. In this review, we aim to discuss the current evidence and controversies of using human albumin for the treatment and prevention of HE in advanced cirrhosis patients. (Source: Metabolic Brain Disease)
Source: Metabolic Brain Disease - May 17, 2023 Category: Neurology Source Type: research
Closing spontaneous portosystemic shunts in cirrhosis: Does it make sense? Does it work? What does it take?
AbstractSpontaneous portosystemic shunts (SPSS) are an often neglected cause of hepatic encephalopathy associated with cirrhosis. Nowadays, SPSS are considered as radiological biomarkers of clinically significant portal hypertension rather than the previous dogmatic perceived decompressive vessels. SPSS are not rare as they can be diagnosed in over 60% of the patients with cirrhosis by mere contrast-enhanced CT. Moreover, they are clinically relevant since they impact on all portal hypertensive related complications, in particular medically refractory HE, and represent an independent predictor of decompensation and mortali...
Source: Metabolic Brain Disease - May 15, 2023 Category: Neurology Source Type: research
Albumin therapy for hepatic encephalopathy: current evidence and controversies
AbstractHepatic encephalopathy (HE) is a common complication that occurs in 16 –21% of end-stage cirrhosis patients. Emerging evidence suggests that systemic inflammation and oxidative stress may play a role in the development of HE. Recent understanding on the anti-inflammatory properties of human albumin has led to growing interest of using human albumin for the treatment and prevention of HE among decompensated patients. In this review, we aim to discuss the current evidence and controversies of using human albumin for the treatment and prevention of HE in advanced cirrhosis patients. (Source: Metabolic Brain Disease)
Source: Metabolic Brain Disease - May 15, 2023 Category: Neurology Source Type: research
miR-181a targets PTEN to mediate the neuronal injury caused by oxygen-glucose deprivation and reoxygenation
The objective of this study was to assess the role of miR-181a in neuronal cell injury after CIRI. To mimic the in-vitro and in-vivo CIRI, we developed an oxygen-glucose deficiency/reoxygenation (OGD/R) model in SH-SY5Y cells and a transient middle cerebral artery occlusion model in rats. MiR-181a expression was significantly higher in both in-vivo and in-vitro CIRI models. The overexpression of miR-181a increased cell damage and oxidative stress caused by OGD/R, whereas inhibition of miR-181a reduced both. PTEN has also been found to be a direct miR-181a target. PTEN overexpression reduced cell apoptosis and oxidative str...
Source: Metabolic Brain Disease - May 13, 2023 Category: Neurology Source Type: research
Special Issue: Pathophysiology, diagnosis, and management of hepatic encephalopathy
(Source: Metabolic Brain Disease)
Source: Metabolic Brain Disease - May 11, 2023 Category: Neurology Source Type: research
Exome sequence analysis of rare frequency variants in Late-Onset Alzheimer Disease
AbstractAlzheimer disease (AD) is a leading cause of dementia in elderly patients who continue to live between 3 and 11 years of diagnosis. A steep rise in AD incidents is observed in the elderly population in East-Asian countries. The disease progresses through several changes, including memory loss, behavioural issues, and cognitive impairment. The etiology of AD is hard to determine because of its complex nature . The whole exome sequences of late-onset AD (LOAD) patients of Korean origin are investigated to identify rare genetic variants that may influence the complex disorder. Computational annotation was performed ...
Source: Metabolic Brain Disease - May 10, 2023 Category: Neurology Source Type: research
Discrepancy of synaptic and microtubular protein phosphorylation in the hippocampus of APP/PS1 and MAPT ×P301S transgenic mice at the early stage of Alzheimer’s disease
AbstractAlzheimer ’s disease (AD) is the most common neurodegenerative disorder, and is caused by multiple pathological factors, such as the overproduction of β-amyloid (Aβ) and the hyperphosphorylation of tau. However, there is limited knowledge of the mechanisms underlying AD pathogenesis and no effective bioma rker for the early diagnosis of this disorder. Thus in this study, a quantitative phosphoproteomics analysis was performed to evaluate global protein phosphorylation in the hippocampus of Aβ overexpressing APP/PS1 transgenic mice and tau overexpressing MAPT×P301S transgenic mice, two in vivo AD mo del system...
Source: Metabolic Brain Disease - May 9, 2023 Category: Neurology Source Type: research
